Huadao Biologics Secures Hundreds of Millions in Series D Funding to Tackle Industry Bottlenecks and Files IPO Prospectus

Investment Circle (ID: pedaily2012) November 16th, by reporter, HuaDao CAR-Tcell has recently completed a D-round financing worth hundreds of millions of yuan. The investors includeCHINT Group Corporation,Sinowisdom, Jiaxing Highway Construction Investment Co.,Ltd., Huzhou Industrial Investment, Hy Energy Group Co.,ltd., Hangzhou Perspective Investment Management Partnership (limited Partnership)etc.

This round of financing will be mainly used for the Phase II project construction of HuaDao CAR-Tcell's Songjiang base and the completion of the Phase II clinical trial of HD CD19 CAR-T injection. While continuing to lead in the full industry chain industrial technology innovation of China’s cellular immunotherapy, the company aims to build a fully independent intellectual property rights, self-pricing cellular drug industry chain transformation platform, making cellular drugs affordable for 80%-90% of Chinese citizens.

HuaDao CAR-Tcell was established in September 2017 with the mission of "making cell drugs affordable for ordinary Chinese people." It is a national high-tech biopharmaceutical enterprise that focuses on the independent innovation, development, and production of cell immunotherapy drugs and their associated whole-industry-chain production technologies (equipment and consumables). HuaDao CAR-Tcell is also the only CAR-T cell drug research and development company in China to have received clinical approval relying on its own industrial technology. The company is currently building cell drug research, development, and transformation production bases in six major central cities across China (East China’s Shanghai Songjiang Base, Southwest China’s Chongqing Bishan Base, Northwest China’s Shaanxi Xianyang Base, Northeast China’s Jilin Changchun Base, South China’s Guangzhou Huangpu Base, and Central China’s Henan Zhengzhou Base).

The first phase of HuaDao CAR-Tcell's East China Shanghai Songjiang Industrial Base was settled in CHINT启迪智电港 last year. During the D-round financing, CHINT Group Corporation, as the "landlord," also officially became a shareholder of HuaDao CAR-Tcell through Zhejiang United Private Investment Co., Ltd.CHINT Group Corporation Vice President Chen ChengjianIt was stated that HuaDao CAR-Tcell, as a key biopharmaceutical enterprise introduced by Songjiang, is a company with a strong sense of social responsibility. Based on shared values, CHINT Group Corporation hopes to empower HuaDao CAR-Tcell by providing comprehensive support, including industrial infrastructure from CHINT启迪智电港 and capital assistance from 浙江民营企业联合投资股份有限公司.

Jiaxing Industrial Asset Investment Group Co., Ltd.Participating in the investment of HuaDao CAR-Tcell's cellular immunotherapy project, as a state-owned enterprise of Jiaxing City, the company is striving to build an outstanding comprehensive investment group in the Yangtze River Delta. Meng Chunhua, member of the Group Party Committee and Deputy General Manager, said: "As one of the initiating cities of the Yangtze River Delta G60 Science and Technology Innovation Corridor, Jiaxing will focus on building an efficient, smooth, collaborative, and orderly G60 Science and Technology Innovation Corridor collaborative innovation system in the Yangtze River Delta, providing strong support for the higher-quality integrated development of the Yangtze River Delta. HuaDao CAR-Tcell is a rising star, and we are fortunate to participate in the investment of its cellular immunotherapy project this time. We hope that HuaDao CAR-Tcell can create more innovations in China."Common People"Affordable cell drugs."

Huzhou Small and Medium Enterprises Venture Capital Co., Ltd.As a state-owned investment platform in Huzhou, it participated in the D-round investment in HuaDao CAR-Tcell. Han Yue, the company's relevant person in charge, said: "As a member of the Yangtze River Delta G60 Science and Technology Innovation Corridor, this investment in HuaDao CAR-Tcell is an important attempt to broaden the investment direction. We also hope that through the government-enterprise-capital exchange platform built by HuaDao CAR-Tcell, we can learn from Shanghai’s whole-industry-chain independent innovation model to guide and encourage the upgrading and development of local industries in Huzhou, advancing together towards independent innovation in China."New Industry"The road of development."

Zong Peimin, Chairman of SinowisdomRepresentation: Why does Sinowisdom decide to double the valuation and increase its investment in HuaDao CAR-Tcell less than a year after the C-round funding? This is because HuaDao CAR-Tcell is in a track with infinite imagination space, and cell therapy is likely to be the ultimate way of human medical technology. At the same time, HuaDao CAR-Tcell has aspirations, strategy, core technology, and super strong action ability. It has developed the world's cheapest cell drug and built up an industrial operation network covering all over China, laying a solid foundation for becoming a CDMO in the cell drug industry. We believe that HuaDao CAR-Tcell will become the pride of Sinowisdom and a bright star worth billions in the capital market!

Yu Xuejun, Chairman and General Manager of HuaDao CAR-TcellYu Xuejun, Chairman of HuaDao CAR-Tcell, stated that the development of cell-based drugs cannot proceed without financial support. Especially as HuaDao CAR-Tcell is currently transitioning from a pure cell drug research and development company to a platform enterprise encompassing R&D, production, and transformation of cell drugs. The goal of HuaDao CAR-Tcell is not only to make cell drugs "affordable" for ordinary people but also to ensure they are "accessible." "We express our gratitude to the local governments of Songjiang in Shanghai, Bishan in Chongqing, and other regions for their comprehensive support, including land and funding exceeding hundreds of millions of yuan. We, the people of HuaDao, will remain true to our original aspiration, live up to expectations, and fulfill our mission by building HuaDao CAR-Tcell into an enterprise that truly adds value to the nation, society, and human health," said Yu Xuejun.